Speece Thorson Capital Group Inc. Sells 12,678 Shares of DaVita Inc. (NYSE:DVA)

Speece Thorson Capital Group Inc. trimmed its position in DaVita Inc. (NYSE:DVA - Free Report) by 12.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,740 shares of the company's stock after selling 12,678 shares during the quarter. DaVita accounts for approximately 2.9% of Speece Thorson Capital Group Inc.'s holdings, making the stock its 16th biggest holding. Speece Thorson Capital Group Inc. owned about 0.12% of DaVita worth $14,187,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP increased its stake in shares of DaVita by 9.1% in the fourth quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock worth $405,000 after buying an additional 227 shares during the period. Fifth Third Bancorp boosted its holdings in DaVita by 5.0% in the first quarter. Fifth Third Bancorp now owns 4,274 shares of the company's stock valued at $654,000 after acquiring an additional 204 shares in the last quarter. Concurrent Investment Advisors LLC bought a new stake in DaVita in the first quarter valued at $223,000. Wealth Enhancement Advisory Services LLC boosted its holdings in DaVita by 22.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company's stock valued at $666,000 after acquiring an additional 800 shares in the last quarter. Finally, OneDigital Investment Advisors LLC bought a new stake in DaVita in the first quarter valued at $200,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on DVA shares. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Truist Financial cut their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, DaVita currently has an average rating of "Hold" and an average target price of $164.50.

DaVita Stock Down 0.2%

Shares of DVA stock traded down $0.30 during mid-day trading on Wednesday, reaching $140.23. 655,543 shares of the company's stock traded hands, compared to its average volume of 811,077. DaVita Inc. has a 12 month low of $131.76 and a 12 month high of $179.60. The company has a market cap of $10.59 billion, a P/E ratio of 13.90, a P/E/G ratio of 0.97 and a beta of 1.11. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 23.18. The company's 50-day moving average price is $140.16 and its 200-day moving average price is $148.67.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The firm had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter in the previous year, the business posted $2.26 EPS. The company's quarterly revenue was up 5.0% on a year-over-year basis. On average, equities analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.